SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-040697
Filing Date
2023-02-16
Accepted
2023-02-16 07:10:03
Documents
14
Period of Report
2023-02-15
Items
Item 2.02: Results of Operations and Financial Condition
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d357370d8k.htm   iXBRL 8-K 33469
2 EX-99.1 d357370dex991.htm EX-99.1 11690
6 GRAPHIC g357370snap0129.jpg GRAPHIC 8146
  Complete submission text file 0001193125-23-040697.txt   186389

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA tals-20230215.xsd EX-101.SCH 2844
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE tals-20230215_lab.xml EX-101.LAB 17978
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tals-20230215_pre.xml EX-101.PRE 11254
8 EXTRACTED XBRL INSTANCE DOCUMENT d357370d8k_htm.xml XML 3345
Mailing Address 93 WORCESTER STREET WELLESLEY MA 02481
Business Address 570 PRESTON ST. SUITE 400 LOUISVILLE KY 40202 502-398-9250
Talaris Therapeutics, Inc. (Filer) CIK: 0001827506 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40384 | Film No.: 23637113
SIC: 2836 Biological Products, (No Diagnostic Substances)